Racial differences in the expression of cell cycle–regulatory proteins in breast carcinoma

African‐American (AA) women are more likely to be diagnosed with an advanced stage of breast carcinoma than are white women. After adjustment for disease stage, many studies indicate that tumors in AA women are more likely than tumors in white women are to exhibit a high level of cell proliferation and features of poor prognosis. The purpose of the current study was to compare tumor characteristics and cell cycle alterations in AA women and white women that might affect the aggressiveness of breast carcinoma.

[1]  B. Trock.  Breast cancer in African American women: Epidemiology and tumor biology , 2005, Breast Cancer Research and Treatment.

[2]  V. Steele,et al.  Cell Proliferation, Apoptosis, and Expression of Cyclin D1 and Cyclin E as Potential Biomarkers in Tamoxifen-Treated Mammary Tumors , 2003, Breast Cancer Research and Treatment.

[3]  S. Ahn,et al.  p16INK4a protein expression is associated with poor survival of the breast cancer patients after CMF chemotherapy , 2001, Breast Cancer Research and Treatment.

[4]  K. Milde-Langosch,et al.  Overexpression of the p16 Cell Cycle Inhibitor in Breast Cancer is Associated with a More Malignant Phenotype , 2001, Breast Cancer Research and Treatment.

[5]  G. Landberg,et al.  G1‐S transition defects occur in most breast cancers and predict outcome , 1999, Breast Cancer Research and Treatment.

[6]  Robert L. Sutherland,et al.  Cyclins and Breast Cancer , 1996, Journal of Mammary Gland Biology and Neoplasia.

[7]  A. Zaloznik.  Breast cancer stage at diagnosis: Caucasians versus Afro-Americans , 1995, Breast Cancer Research and Treatment.

[8]  Jose M. Silva,et al.  Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. , 2003, Mutation research.

[9]  J. Palmer,et al.  Dual effect of parity on breast cancer risk in African-American women. , 2003, Journal of the National Cancer Institute.

[10]  K. Malone,et al.  Differences in breast cancer stage, treatment, and survival by race and ethnicity. , 2003, Archives of internal medicine.

[11]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[12]  V. Shavers,et al.  Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35 , 2003, Cancer.

[13]  L. Bernstein,et al.  Ethnicity‐related variation in breast cancer risk factors , 2003, Cancer.

[14]  V. Pinn,et al.  Histopathology of breast cancer among African‐American women , 2003, Cancer.

[15]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[16]  L. Brinton,et al.  Oral contraceptive use and cyclin D1 overexpression in breast cancer among young women. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[17]  G. Landberg,et al.  The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node , 2002, Oncogene.

[18]  L. Newman,et al.  Ethnicity related differences in the survival of young breast carcinoma patients , 2002, Cancer.

[19]  G. Colditz,et al.  African‐American ethnicity, socioeconomic status, and breast cancer survival , 2002, Cancer.

[20]  O. Brawley.  Disaggregating the effects of race and poverty on breast cancer outcomes. , 2002, Journal of the National Cancer Institute.

[21]  Cathy J Bradley,et al.  Race, socioeconomic status, and breast cancer treatment and survival. , 2002, Journal of the National Cancer Institute.

[22]  P. Porter,et al.  The relation of reproductive factors to mortality from breast cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[23]  G. Landberg.  Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis. , 2002, Advances in cancer research.

[24]  M. Gnant,et al.  Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Blamey,et al.  INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Pathak,et al.  Breast carcinoma etiology , 2000, Cancer.

[27]  R. Millikan,et al.  Risk of breast cancer according to the status of HER-2/neu oncogene amplification. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  J. Elmore,et al.  Breast carcinoma tumor characteristics in black and white women , 1998, Cancer.

[29]  C. Markopoulos,et al.  Alterations of p16-pRb Pathway and Chromosome Locus 9p21–22 in Sporadic Invasive Breast Carcinomas , 1998, Molecular medicine.

[30]  S. Groshen,et al.  Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.

[31]  Philip Smith,et al.  Retinoblastoma and p16 proteins in mammary carcinoma: Their relationship to cyclin D1 and histopathological parameters , 1998, International journal of cancer.

[32]  F. O'Malley,et al.  Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast. , 1997, The American journal of pathology.

[33]  M. Loda,et al.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. , 1997, Cancer research.

[34]  James M. Roberts,et al.  Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients , 1997, Nature Medicine.

[35]  Herman Yeger,et al.  Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.

[36]  G. Landberg,et al.  Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein , 1997, Oncogene.

[37]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[38]  G. Landberg,et al.  Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. , 1996, British Journal of Cancer.

[39]  J. Geradts,et al.  High frequency of aberrant p16(INK4A) expression in human breast cancer. , 1996, The American journal of pathology.

[40]  A. Harris,et al.  p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. , 1996, British Journal of Cancer.

[41]  G. Peters,et al.  Cyclin D1 and prognosis in human breast cancer , 1996, International journal of cancer.

[42]  H. Matsuda,et al.  Inversely correlated expression of p16 and Rb protein in non‐small cell lung cancers: An immunohistochemical study , 1996, International journal of cancer.

[43]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[44]  R. Hoover,et al.  Oral contraceptives and breast cancer risk among younger women. , 1995, Journal of the National Cancer Institute.

[45]  James M. Roberts,et al.  Human cyclin E, a nuclear protein essential for the G1-to-S phase transition , 1995, Molecular and cellular biology.

[46]  S. Joslyn.  Racial differences in survival from breast cancer. , 1995, JAMA.

[47]  P. Tartter,et al.  Ethnic differences in risk and prognostic factors for breast cancer. , 1995, Cancer.

[48]  C. Sherr.  G1 phase progression: Cycling on cue , 1994, Cell.

[49]  T. Hunter,et al.  Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.

[50]  C K Redmond,et al.  Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. , 1994, JAMA.

[51]  R. Elledge,et al.  p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. , 1994, Cancer research.

[52]  D. Slamon,et al.  Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.

[53]  G M Clark,et al.  Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. , 1994, Journal of the National Cancer Institute.

[54]  C. Redmond,et al.  Histological characteristics of breast carcinoma in blacks and whites. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[55]  R. Cote,et al.  Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques , 1994, Human pathology.

[56]  D. Marchant,et al.  Risk factors. , 1994, Obstetrics and gynecology clinics of North America.

[57]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[58]  C. Redmond,et al.  Breast cancer: factors associated with stage at diagnosis in black and white women. Black/White Cancer Survival Study Group. , 1993, Journal of the National Cancer Institute.

[59]  B. Trock,et al.  Impact of an HMO-based intervention to increase mammography utilization. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[60]  Johannes Gerdes,et al.  Monoclonal antibodies against recombinant parts of the Ki‐67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave‐processed formalin‐fixed paraffin sections , 1992, The Journal of pathology.

[61]  V W Chen,et al.  Treatment plans for black and white women with stage II node‐positive breast cancer: The national cancer institute black/white cancer survival study experience , 1992, Cancer.

[62]  J. Gerdes,et al.  Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. , 1992, The Journal of pathology.

[63]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[64]  J. Herndon,et al.  Relation between p53 overexpression and established prognostic factors in breast cancer. , 1991, Surgery.

[65]  A. Arnold,et al.  A novel cyclin encoded by a bcl1-linked candidate oncogene , 1991, Nature.

[66]  C. Purdie,et al.  p53 expression in colorectal tumors. , 1991, The American journal of pathology.

[67]  J. Bartek,et al.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.

[68]  S. Shousha,et al.  Immunohistological study of oestrogen receptors in breast carcinomas that are biochemically receptor negative. , 1990, Journal of clinical pathology.

[69]  H. Poulsen,et al.  Immunohistochemical estrogen receptor determination in paraffin‐embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer , 1989, Cancer.

[70]  F. Parl,et al.  Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. , 1988, Human pathology.

[71]  K. Rogers,et al.  Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand binding assays and oestrogen receptor immunohistology. , 1988, Journal of clinical pathology.

[72]  J. Russo,et al.  Racial differences in breast cancer patients. , 1985, Journal of the National Cancer Institute.

[73]  S. Hsu,et al.  Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  L. D. Leffall.  Breast cancer in black women , 1981, CA: a cancer journal for clinicians.

[75]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[76]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.